Login / Signup

Improvement of the Metabolic Stability of GPR88 Agonist RTI-13951-33: Design, Synthesis, and Biological Evaluation.

Md Toufiqur RahmanAnn M DeckerSami Ben HamidaDavid A PerreyHetti Handi Chaminda LakmalRangan MaitraEmmanuel DarcqBrigitte L KiefferChunyang Jin
Published in: Journal of medicinal chemistry (2023)
GPR88 is an orphan G protein-coupled receptor mainly expressed in the brain, whose endogenous ligand has not yet been identified. To elucidate GPR88 functions, our group has developed RTI-13951-33 ( 1b ) as the first in vivo active GPR88 agonist, but its poor metabolic stability and moderate brain permeability remain to be further optimized. Here, we report the design, synthesis, and pharmacological characterization of a new series of RTI-13951-33 analogues with the aim of improving pharmacokinetic properties. As a result, we identified a highly potent GPR88 agonist RTI-122 ( 30a ) (cAMP EC 50 = 11 nM) with good metabolic stability (half-life of 5.8 h) and brain permeability (brain/plasma ratio of >1) in mice. Notably, RTI-122 was more effective than RTI-13951-33 in attenuating the binge-like alcohol drinking behavior in the drinking-in-the-dark paradigm. Collectively, our findings suggest that RTI-122 is a promising lead compound for drug discovery research of GPR88 agonists.
Keyphrases
  • fatty acid
  • resting state
  • white matter
  • drug discovery
  • cerebral ischemia
  • type diabetes
  • metabolic syndrome
  • photodynamic therapy
  • skeletal muscle
  • high intensity
  • adipose tissue
  • insulin resistance